Scarica l'app Stockscreener
9.32
0.43%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$9.28
Aprire:
$9.28
Volume 24 ore:
321.10K
Relative Volume:
0.65
Capitalizzazione di mercato:
$6.34B
Reddito:
$7.94B
Utile/perdita netta:
$225.54M
Rapporto P/E:
28.25
EPS:
0.3299
Flusso di cassa netto:
$709.16M
1 W Prestazione:
+0.43%
1M Prestazione:
+5.43%
6M Prestazione:
-12.41%
1 anno Prestazione:
+24.77%
Intervallo 1D:
$9.27
$9.38
Intervallo di 1 settimana:
$9.0701
$9.635
Portata 52W:
$6.19
$11.14
Grifols Sa Adr Stock (GRFS) Company Profile
Nome
Grifols Sa Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare GRFS vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
9.32 | 6.32B | 7.94B | 225.54M | 709.16M | 0.3299 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Ripresa | Morgan Stanley | Overweight |
| 2024-03-12 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-04-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Downgrade | Barclays | Overweight → Underweight |
| 2021-10-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-06-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Iniziato | Deutsche Bank | Hold |
| 2021-03-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2020-10-01 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-06-09 | Downgrade | Citigroup | Neutral → Sell |
| 2020-06-09 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Downgrade | Citigroup | Buy → Neutral |
| 2019-06-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Downgrade | Berenberg | Buy → Hold |
| 2018-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-06-01 | Iniziato | Barclays | Overweight |
| 2017-10-31 | Iniziato | Citigroup | Buy |
| 2017-06-30 | Downgrade | Goldman | Buy → Neutral |
| 2017-04-06 | Iniziato | BofA/Merrill | Buy |
| 2017-01-03 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Aggiornamento | Berenberg | Hold → Buy |
| 2016-01-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Downgrade | HSBC Securities | Buy → Hold |
| 2015-11-20 | Downgrade | Berenberg | Buy → Hold |
| 2015-04-28 | Downgrade | Berenberg | Buy → Hold |
Mostra tutto
Grifols Sa Adr Borsa (GRFS) Ultime notizie
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar Australia
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Grifols: Brookfield's potential $6.8 bln offer undervalues the firm - Reuters
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar Canada
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF - Macau Business
San Gabriel Valley Tribune - FinancialContent
Cramer 'Takes A Pass' On Stock That's Down 31% Over Past 6 Months: 'Don't Want To Go Against Musk' - Sahm
GRFS Stock Quote Price and Forecast - CNN
Grifols S.A. Investigated by Block & Leviton For Potential - GlobeNewswire
Which Trades Are Top Funds Making? - Morningstar Canada
Shares at Spain's Grifols rise on cost-cutting plan - Reuters
Grifols SA US (GRFS) Stock Price, News & Analyst Forecast - eToro
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - Newswire Canada
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation - Stock Titan
Grifols Sa Adr Azioni (GRFS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):